Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1569912 add-on therapy for MDD with inadequate antidepressant response
CTR20242430Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI 1569912 in major depressive disorder (MDD), sponsored by Boehringer Ingelheim. Started Jul 2024; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20242430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242430.